Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hilary Chaudri Ross

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|September 12, 2007
Conditional approval: discussion points from the PSI conditional approval expert groupKevin Carroll, Hilary Chaudri Ross, Dan Evans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer GroupHenning Mouridsen, Mikhail Gershanovich, Yan Sun, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|September 12, 2007
Conditional approval: discussion points from the PSI conditional approval expert groupKevin Carroll, Hilary Chaudri Ross, Dan Evans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer GroupHenning Mouridsen, Mikhail Gershanovich, Yan Sun, et al.
Pageof 1